Maria Gutierrez Dorrington
Boynton Beach, FLNPI 1578585816
Payments from drug & device makers
Across 981 payments — averaging $171.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$70K
- Mannkind Corporation$33K
- Bayer$24K
- AstraZeneca$17K
- Medtronic$10K
- Sanofi-aventis U.S. LLC$2K
- plus $12K from 47 others
What the payments were for
- Consulting fees$5,3913%
- Speaking & faculty fees$112,34067%
- Grants$10,0006%
- Travel & lodging$19,05711%
- Food & beverage$21,79013%
- Education$320%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$68,673
- AFREZZA$24,958
- Kerendia$23,234
- FARXIGA$15,713
- V-GO$7,158
- Repatha$967
- NEXLIZET$250
- NEXLETOL$250
- TZIELD$248
- XARELTO$246
- Ozempic$228
- Wegovy$226
- t-slim insulin pump$221
- Synthroid$205
- DEXCOM G7 GSS (161)$143
- DEXCOM STELO GLUCOSE BIOSENSOR$143
- SOMATULINE DEPOT$125
- TEPEZZA$125
- Tymlos$120
- t:slim X2 insulin pump$120
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 84 | $105,254 |
| MounjaroTirzepatide | 47 | $52,645 |
| FarxigaDapagliflozin Propanediol | 28 | $33,472 |
| JardianceEmpagliflozin | 26 | $22,935 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $13,505 |
| SynthroidLevothyroxine Sodium | 58 | $4,424 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,614 |
| Levothyroxine Sodium | 135 | $1,477 |
| Liothyronine Sodium | 23 | $880 |
| Pioglitazone Hcl | 24 | $589 |
| ProgesteroneProgesterone, Micronized | 14 | $586 |
| Rosuvastatin Calcium | 35 | $578 |
| Metformin Hcl | 83 | $520 |
| Repaglinide | 15 | $502 |
| Ezetimibe | 11 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,000 | $105,25484 claims |
| Lilly USA, LLCMounjaro | $974 | $52,64547 claims |
| AstraZenecaFarxiga | $16,856 | $33,47228 claims |
| Boehringer IngelheimJardiance | $370 | $22,93526 claims |
| AbbVieSynthroid | $595 | $4,42458 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $279 | $1,477135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.